cluded progression to hindbrain decompression, complications of hindbrain decompression caused by elevated ICP, and radiographically demonstrated resolution of the syrinx.
Results

Patient Population
Sixteen patients with CM-I and hydrocephalus underwent ETV. All patients had ventriculomegaly together with symptoms and signs of elevated ICP. (Note that we perform ICP monitoring in patients with CM-I and small ventricles only if symptoms suggestive of increased ICP are also present.) There were 9 male and 7 female patients, with a mean age of 31.9 years (range 2-68 years) at presentation. The mean duration of follow-up was 42 months (range 6-96 months). One patient had Noonan syndrome, and 1 patient had previously had a head injury. No other patient had a history of neurological disease.
Fifteen patients underwent primary ETV, and 1 patient underwent ETV at the time of shunt malfunction. No patient in the series had undergone any previous surgical intervention to address the CM-I.
Symptom Categories
For the purposes of analysis we classified presenting symptoms into 3 groups: Group 1, elevated ICP-related symptoms (for example, global headache, vomiting, visual obscuration, papilledema, cranial nerve VI palsy, developmental delay, or increasing head circumference); Group 2, classic CM-related symptoms plus elevated ICP (for example, cough-induced occipital headache, ataxia, or facial or upper limb symptoms in the absence of a syrinx); and Group 3, syringomyelia plus elevated ICP (for example, dissociated sensory loss or upper limb weakness and wasting). All patients demonstrated symptoms of raised ICP.
Neuroimaging Studies
All patients underwent T1-and T2-weighted MR imaging studies of the brain and spine with phase-contrast CSF flow studies. A neuroradiologist (K.D.) reviewed all images. All patients demonstrated CM-I with a mean 15-mm herniation of the cerebellar tonsils below the basion-opisthion line. All patients had ventriculomegaly. Twelve patients were characterized as having a small posterior fossa based on the presence of a low-lying confluence of sinuses, a reduction in the height of the occipital bone, and accentuation of the slope of the tentorium cerebelli with crowding of the posterior fossa contents (volumetric measurements were not obtained). Three patients also had aqueductal stenosis and 2 had a retrocerebellar arachnoid cyst. Six patients had a spinal cord syrinx. In the 4 patients who did not have posterior fossa osseous abnormalities, 2 had aqueductal stenosis and 1 had a retrocerebellar arachnoid cyst to account for the tonsillar ectopia; 2 of these 4 patients required subsequent foramen magnum decompression.
The mean level of tonsillar herniation following ETV was 13.3 mm, and the size of the ventricle reduced in only 5 patients. In the patients with aqueductal stenosis only 1 had evidence of posterior fossa osseous abnormalities, and the single ETV failure occurred in 1 patient with aqueductal stenosis.
Primary Outcome: Shunt Independence
Fifteen patients (94%) remained shunt free following ETV. The single case of ETV failure occurred in a 54-yearold woman who had previously undergone VP shunt placement for hydrocephalus associated with CM-I. She presented with headaches and right facial numbness caused by shunt obstruction as well as ventriculomegaly and aqueductal stenosis with CM-I on MR imaging. After ETV and shunt removal she continued to experience cough-induced headaches and facial numbness, and she underwent foramen magnum decompression 2 months after ETV. Her symptoms remained resolved for 2 years but then later recurred; a repeated ETV revealed a patent stoma, and a VP shunt was inserted.
Secondary Outcome: Symptom Resolution According to Symptom Category
Symptom resolution after ETV, according to symptom category, is featured in Table 1 . All patients had symptoms of elevated ICP, and in 3 patients ICP-related symptoms were the only ones. Elevated ICP-related symptoms resolved in all patients following ETV. Eight patients had CM-associated symptoms in addition to those due to raised ICP, mainly cough-induced headache. Five patients presented with syringomyelia in addition to symptoms of increased ICP. Three patients with syringomyelia experienced improvement or resolution of their symptoms following ETV. Of the 8 patients with CM-I symptoms without syringomyelia, 4 experienced complete symptom resolution after ETV. The remaining 4 patients required subsequent foramen magnum decompression.
Progression to Hindbrain Decompression
Among the 16 patients, 6 (37.5%) required foramen magnum decompression following initial management with ETV. The mean time to decompression surgery was 6 months after the initial ETV (range 0.5-12 months). All 6 patients demonstrated minimal improvement in symptoms (other than those of raised ICP) following initial ETV, including strain-related headache. All 6 patients had resolution of strain-related headache following hindbrain decompression, and no patient suffered hydrocephalus-related complications at the time of decompression. All patients had improvement of facial and upper limb symptoms; however, 4 patients continue to have intermittent upper limb sensory disturbance.
Procedural Complications
In 1 patient a small extradural hematoma was demonstrated on postoperative imaging after ETV. This lesion was asymptomatic and thus was managed conservatively. There were no other complications related to ETV. In patients who had progressed to hindbrain decompression there were no complications as a result of raised ICP, such as CSF leakage; however, 1 patient had bilateral small subdural hygromas, which were managed conservatively and resolved.
Incidence of Syringomyelia
Six patients had a spinal cord syrinx (all cervicothoracic) on presentation. The largest syrinx extended from C-1 to T-9. The syrinx reduced in length and caliber following ETV in 4 patients, and there was complete resolution of the syrinx in 1 patient. These 5 patients had symptoms attributable to the syrinx, such as upper limb weakness or sensory changes. One patient had an asymptomatic syrinx, which remained unchanged after ETV.
Two patients (33%) with syringomyelia had persistent marked symptoms following ETV, despite radiologically demonstrated improvement in the appearance of the cavity, and thus underwent hindbrain decompression. Thereafter, symptoms improved, leaving upper limb sensory changes in 1 patient and upper limb dysesthesia in the other.
Discussion
The descent of the cerebellar tonsils below the foramen magnum was originally described by Chiari 4 in 1891; however, the origin and pathophysiology of this condition remains poorly understood. In his 1891 monograph, Chiari originally surmised that hydrocephalus provided the driving force to push the cerebellar tonsils into the foramen magnum. However, overt hydrocephalus is only reported in 7-10% of patients with symptomatic CM-I. Some have asserted that CM-I is primarily a developmental anomaly of the posterior fossa with subsequent arachnoid adhesions. Therefore, any associated hydrocephalus may be an obstructive phenomenon due to fourth ventricular outflow obstruction. 2 Endoscopic third ventriculostomy has gained widespread acceptance as a durable alternative to ventricular shunt placement for obstructive hydrocephalus. In certain etiological groups, such as isolated aqueductal stenosis, success rates, as determined by shunt freedom, are in the order of 80-90%. [10] [11] [12] Endoscopic third ventriculostomy presents an attractive alternative to ventricular shunt placement given the much lower risk of infection and long-term durability, which appear superior considering potential rates of shunt malfunction. Note, however, that late blockage of ETV stomas have been reported. 6 The principal of a third ventriculostomy can be applied to obstructive hydrocephalus originating distal to the aqueduct; however, the reduction in the size of the prepontine subarachnoid space has been regarded as a limiting factor in these cases. Numerous isolated case reports of successful ETV in patients with CM-I have been published (Table 2) , demonstrating the ability to safely form a stoma in the floor of the third ventricle despite the small size of the prepontine cistern. In addition, published cases have demonstrated success in terms of shunt freedom and symptom resolution. However, Fukuhara et al. 9 have described CM-I as a risk factor for ETV failure, although their study included only 5 patients with CM-I. Our series of patients with CM-I represents the largest to date and reveals the efficacy of ETV in such a cohort of patients.
The majority of patients remain shunt free; however, a proportion will need subsequent foramen magnum decompression because of ongoing symptoms other than those associated with elevated ICP. This issue has not been specifically addressed in the literature. Decq and associates 5 have suggested that there is a subset of patients whose symptoms are solely attributable to a disturbance in CSF flow and that the treatment of the CM in such cases is not mandatory. Identifying this subset prior to any intervention is difficult, however, as these patients do not consist of only those who have ventricular dilation. Although a significant proportion of patients with CM-I appear to have posterior fossa osseous abnormalities leading to a reduced volume of the posterior fossa, 1, 15, 22 those without a small posterior fossa in the present study did not have a lower rate of progression to foramen magnum decompression. Nonetheless, we agree that a proportion of patients with CM will have tonsillar ectopia due to primary aqueductal stenosis or idiopathic intracranial hypertension. 8 It is clear from these results that CM-I is a heterogeneous entity, with multiple underlying pathological mechanisms even within each patient, and intracranial hypertension constitutes only one.
Syringomyelia is associated with hindbrain herniation in 50-76% of cases. 7, 18 The mechanism of development and progression of the cavity has been extensively investigated by Williams, 25 who described a valve mechanism at the foramen magnum that created a craniospinal CSF pressure dissociation, allowing syrinx formation. Dynamic imaging appears to confirm this process, showing blockage of CSF flow at the foramen magnum during systole, which in turn causes a pressure wave in spinal CSF. 21 In addition, Oi et al. 20 proposed the entity of communicating hydromyelic hydrocephalus as a progression of untreated hydrocephalus, with subsequent isolation of the cord cavity following shunting. However, the majority of patients with syringomyelia and CM-I have so-called "noncommunicating" syringomyelia with cavities commencing in the midcervical region prior to any intervention. 23 In patients in whom hydrocephalus is evident, initial ventricular decompression is accepted as standard practice before addressing the hindbrain hernation.
24,25 Krayenbuhl 13 reported on a series of 22 patients with syringomyelia who were initially treated with ventriculoatrial shunt placement; 20 patients experienced improvement in their symptoms. Ogilvy and Borges 19 have described MR imaging evidence of a reduction in the size of a cervical syrinx following insertion of a VP shunt and associated symptomatic improvement. Such improvement has also been documented after ETV in isolated case reports. 3, 14, 16, 17 In the present study ETV resulted in radiologically demonstrated improvement or resolution of the syrinx in 5 patients (83%), although 2 patients (33%) required subsequent hindbrain decompression for ongoing syringomyelia symptoms.
Among our series of patients there was a low complication rate with no permanent sequelae. There were no episodes of CSF leakage, even at the time of hindbrain decompression, when one might expect CSF leakage if a ventricular system is not adequately decompressed and elevated ICP persists. Therefore, we advocate replacing ventricular shunt insertion with ETV in the management of CM-I associated with hydrocephalus. In up to 60% of cases ETV, with its very low complication rate, can provide definitive management and thus avoid unnecessary hindbrain decompression.
Conclusions
Endoscopic third ventriculostomy provides a durable form of treatment for hydrocephalus associated with CM-I. It is effective as the primary means of management, and we advocate replacing routine VP shunt insertion in patients with this combination of pathophysiologies. Management of the hydrocephalus alone is often sufficient to alleviate symptoms associated with the CM-I and any associated syringomyelia and can obviate subsequent decompression. Note, however, that a significant proportion of patients will still need both procedures, and complications due to elevated ICP are not seen at the time of decompression.
